- Home
- DMAC vs MRCC Comparison
DMAC vs MRCC Comparison
Compare DMAC & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- MRCC
- Stock Information
- Founded
- DMAC 2000
- MRCC 2011
- Country
- DMAC United States
- MRCC United States
- Employees
- DMAC N/A
- MRCC N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- MRCC Investment Managers
- Sector
- DMAC Health Care
- MRCC Finance
- Exchange
- DMAC Nasdaq
- MRCC Nasdaq
- Market Cap
- DMAC 158.1M
- MRCC 176.4M
- IPO Year
- DMAC N/A
- MRCC 2012
- Fundamental
- Price
- DMAC $4.11
- MRCC $6.45
- Analyst Decision
- DMAC Strong Buy
- MRCC Hold
- Analyst Count
- DMAC 2
- MRCC 1
- Target Price
- DMAC $8.00
- MRCC $8.00
- AVG Volume (30 Days)
- DMAC 102.4K
- MRCC 101.1K
- Earning Date
- DMAC 05-13-2025
- MRCC 05-07-2025
- Dividend Yield
- DMAC N/A
- MRCC 15.50%
- EPS Growth
- DMAC N/A
- MRCC 3301.50
- EPS
- DMAC N/A
- MRCC 0.32
- Revenue
- DMAC N/A
- MRCC $56,983,000.00
- Revenue This Year
- DMAC N/A
- MRCC N/A
- Revenue Next Year
- DMAC N/A
- MRCC N/A
- P/E Ratio
- DMAC N/A
- MRCC $19.85
- Revenue Growth
- DMAC N/A
- MRCC N/A
- 52 Week Low
- DMAC $2.14
- MRCC $6.11
- 52 Week High
- DMAC $6.82
- MRCC $8.85
- Technical
- Relative Strength Index (RSI)
- DMAC 50.90
- MRCC 42.64
- Support Level
- DMAC $3.92
- MRCC $6.31
- Resistance Level
- DMAC $4.33
- MRCC $6.46
- Average True Range (ATR)
- DMAC 0.29
- MRCC 0.17
- MACD
- DMAC 0.02
- MRCC 0.03
- Stochastic Oscillator
- DMAC 56.79
- MRCC 70.83
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.